Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) EBITDA (2020 - 2025)

NeuroPace has reported EBITDA over the past 6 years, most recently at -$1.8 million for Q4 2025.

  • Quarterly results put EBITDA at -$1.8 million for Q4 2025, up 51.63% from a year ago — trailing twelve months through Dec 2025 was -$16.3 million (up 32.86% YoY), and the annual figure for FY2025 was -$16.3 million, up 24.61%.
  • EBITDA for Q4 2025 was -$1.8 million at NeuroPace, up from -$2.6 million in the prior quarter.
  • Over the last five years, EBITDA for NPCE hit a ceiling of -$1.8 million in Q4 2025 and a floor of -$13.2 million in Q2 2022.
  • Median EBITDA over the past 5 years was -$8.3 million (2021), compared with a mean of -$7.9 million.
  • Biggest five-year swings in EBITDA: crashed 139.82% in 2021 and later soared 51.63% in 2025.
  • NeuroPace's EBITDA stood at -$11.0 million in 2021, then increased by 0.71% to -$10.9 million in 2022, then surged by 43.22% to -$6.2 million in 2023, then surged by 41.08% to -$3.7 million in 2024, then soared by 51.63% to -$1.8 million in 2025.
  • The last three reported values for EBITDA were -$1.8 million (Q4 2025), -$2.6 million (Q3 2025), and -$6.8 million (Q2 2025) per Business Quant data.